Ligand Pharma (LGND) PT Raised to $345 at RBC Capital

August 7, 2026 7:21 AM

RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $345.00 (from $340.00) while maintaining a Outperform rating.

No results found